Table 3.
Multidrug resistance in in vitro models.
| Model | Treatment | RI | Drugs tested for cross-resistance | ABCB1/PGP overexpression | Reference | |
|---|---|---|---|---|---|---|
| No cross- | Cross-resistance | |||||
| resistance | ||||||
| Serra_U2OS/MTX-C | MTX | 135 | DOX | TRIM | Y | [34, 37] |
| Mukherjee_HOS/CDDP-P | CDDP | 2.2 | – | 5-FU | Y | [41] |
| Partial MAP resistance | ||||||
| Serra_U2OS/DOX-C | DOX | 330 | – | MTX | Y | [34] |
| Serra_SAOS2/DOX-C | DOX | 338 | – | MTX | Y | [34] |
| Shen_U2OS/DOX-P | DOX | 95.6 | – | CDDP, PAC | Y | [44] |
| Shen_MG63/DOX-P | DOX | 72.9 | – | CDDP, PAC | Y | [44] |
| Wang_SAOS2/MTX-P | MTX | 12.73 | CDDP | DOX, IFOS, EPI, THP | N | [49] |
| Complete MAP resistance | ||||||
| Serra_SAOS2/MTX-C | MTX | 281 | – | DOX, CDDP, TRIM | Y | [34, 37] |
| Lourda_U2OS/DOX-C | DOX | 15 | – | MTX, CDDP | Y | [72] |
| Lourda_KHOS/DOX-C | DOX | 6.3 | – | MTX, CDDP | Y | [72] |
| Han_SOSP9607/CDDP-P | CDDP | 6.25 | PAC | MTX, DOX | N | [54] |
| Wang_MG63/DOX-C | DOX | 10.53 | – | MTX, CDDP, IFOS | Y | [58] |
| Xu_MG63/DOX-C | DOX | 6 | – | MTX, CDDP | NA | [65] |
Chemoresistant models were generated by exposure to a single MAP agent. Cross-resistance to further MAP drugs, in addition to non-MAP drugs such as (TRIM) Trimetrexate, (PAC) Paclitaxel, (THP) Theprubicin, (EPI) Epirubicin, (5-FU) 5-Fluorouracil, was also investigated in some studies. Models with partial MAP resistance were determined to be cross-resistant to one further MAP drug and include those that were not investigated for complete MAP resistance. Complete MAP resistance identifies models that were determined to be resistant to all MAP agents. Expression of ABCB1/PGP is indicated compared to the respective parental control. (–) No further drugs tested, NA Not tested.